跳至主要内容
临床试验/NCT05203003
NCT05203003招募中不适用

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Assistance Publique - Hôpitaux de Paris1 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2022年4月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
260
试验地点
1
主要终点
Rate of patients that maintain MRD negativity

研究概览

简要总结

We propose to conduct an ancillary prospective evaluation of the impact of Dara-Len-Dex discontinuation after 2 years, on the persistence of MRD negativity in patients that were MRD negative at 2 years.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (≥ 18 years old) who are included in the CONFIRM phase III trial (ClinicalTrials.gov Identifier: NCT03836014).
  • Subject that are still under therapy at 2 years (+/- 3 month) after randomization, either in the fixed duration therapy group or in the continuous therapy group of the CONFIRM protocol
  • Subject in complete response at 2 years (+/- 3 month) after randomization.
  • Signed informed consent
  • Affiliation to a social security system or equivalent

排除标准

  • 未提供

结局指标

主要结局

Rate of patients that maintain MRD negativity

时间窗: 3 and 4 years after inclusion

Rate of patients that maintain MRD negativity at 3 and 4 years after inclusion in the current protocol in the continuous Dara-Len-Dex therapy group versus fixed duration Dara-Len-Dex therapy (2 years) group.

次要结局

  • PFS at 2 years(2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验